First‑Line Antihypertensive Therapy in Patients with Coronary Artery Disease
1. Guideline‑based drug class selection
- The Canadian Cardiovascular Society (CCS) recommends an ACE inhibitor or an ARB as the first‑line antihypertensive agent for virtually all patients who have both hypertension and coronary artery disease, citing Grade A evidence. 1
- For patients with stable angina, the CCS gives beta‑blockers a preferred status (Grade B), but ACE inhibitors remain recommended for the broader coronary‑disease population. 1
- In non‑Black patients with uncomplicated hypertension, ACE inhibitors have Grade B evidence of efficacy; however, the presence of coronary disease makes ACE inhibition a compelling indication irrespective of race. 5
2. When to start monotherapy vs. fixed‑dose combination
| Blood‑pressure situation | Recommended initial strategy | Guideline source & evidence grade |
|---|---|---|
| Stage 1 hypertension (130‑139/80‑89 mmHg) or < 20/10 mmHg above target | Begin with a single first‑line agent (e.g., lisinopril) and add additional agents only if needed. | ACC/AHA 2025 (Grade A) – cited in Circulation. [3] |
| Stage 2 hypertension (≥140/90 mmHg) or BP ≥20/10 mmHg above target | Initiate a two‑drug single‑pill combination of first‑line agents (e.g., lisinopril + hydrochlorothiazide). | ACC/AHA 2025 (Grade A) and ESC 2024 (Grade A) – cited in Circulation and European Heart Journal. [3, 4] |
3. Benefits of an ACE‑inhibitor + thiazide single‑pill combination
- The CCS grades the lisinopril + hydrochlorothiazide combination as a Grade B recommended regimen for hypertension in coronary‑disease patients. 5, 6
- Fixed‑dose combinations improve medication adherence and achieve blood‑pressure control more rapidly than separate pills. (Evidence Grade A) 3, 4
- Adding a thiazide diuretic to an ACE inhibitor provides additive blood‑pressure‑lowering effects and reduces the risk of both hypokalemia and hyperkalemia compared with either drug alone. (Evidence Grade A) 3
4. Safety and monitoring considerations
- Initiating combination therapy in patients who may not tolerate a large acute BP drop requires caution; clinicians should monitor for symptomatic hypotension, especially in volume‑depleted individuals. (Grade B) 5, 6
- Lisinopril monotherapy can modestly raise serum potassium, whereas the addition of a thiazide tends to lower potassium; the combined regimen balances these effects, lowering the overall risk of electrolyte disturbance. (Evidence Grade A) 3
5. Alternatives and contraindications
- If an ACE inhibitor is not tolerated (e.g., cough), an ARB can be substituted and provides equivalent cardiovascular protection in coronary disease (Grade A). 1
- Co‑administration of an ACE inhibitor with an ARB is not recommended and may be harmful; all major guidelines advise against this combination. (Grade B) 5, 6, 3
6. Adjunctive coronary‑disease therapy
- The 2024 ESC chronic coronary syndrome guideline advises lifelong low‑dose aspirin (75‑100 mg daily) for patients with documented obstructive coronary artery disease. (Grade A) 2